FDMT — 4D Molecular Therapeutics Share Price
Last Trade - 00:00- $791.67m
- $531.81m
- $13.61m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 5.79 | 14.13 | 6.99 | 13.61 | 3.6 | 3.55 | 32.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
4D Molecular Therapeutics, Inc. is a clinical-stage stage gene therapy company. The Company is focused on developing targeted therapies based on its adeno-associated viruses (AAV) vectors. It uses its Therapeutic Vector Evolution platform to customize its AAV vectors to target specific tissue types associated with the disease. The Company is focuses on three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector), and pulmonology (aerosol vector). The Company's product candidates include 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), 4D-110 for the treatment of choroideremia, 4D-310 for the treatment of Fabry disease, 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and 4D-710 for the treatment of cystic fibrosis lung disease.
Directors
- John Milligan (60)
- David Kirn CEO (59)
- August Moretti (71)
- David Schaffer (50)
- Robert Fishman (59)
- Carolyne Zimmermann
- Tony Yao (49)
- Jacob Chacko (42)
- Susannah Gray (60)
- Nancy Miller-Rich (62)
- Charles Theuer (57)
- Shawn Tomasello (62)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- March 11th, 2015
- Public Since
- January 1st, 1970
- No. of Shareholders
- 96
- No. of Employees
- 104
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 26,988,255
- Address
- 5858 Horton Street #455, Emeryville, EMERYVILLE, 94608
- Web
- http://www.4dmoleculartherapeutics.com/
- Phone
- +1 5105052680
- Contact
- Mike Zanoni
- Auditors
- PricewaterhouseCoopers LLP
Latest News for FDMT
Upcoming events for FDMT
Similar to FDMT
ABCELLERA BIOLOGICS ORD
NASDAQ Global Select Market
ABSCI ORD
NASDAQ Global Select Market
ACADIA PHARMACEUTICALS ORD
NASDAQ Global Select Market
ACHILLES THERAPEUTICS ADS
NASDAQ Global Select Market
ACLARIS THERAPEUTICS ORD
NASDAQ Global Select Market
FAQ
As of Today at 11:30 UTC, shares in 4D Molecular Therapeutics are trading at $29.60. This share price information is delayed by 15 minutes.
Shares in 4D Molecular Therapeutics last closed at $29.60 and the price had moved by over the past 365 days. In terms of relative price strength the 4D Molecular Therapeutics share price has matched the S&P500 Index by over the past year.
The overall consensus recommendation for 4D Molecular Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
4D Molecular Therapeutics does not currently pay a dividend.
4D Molecular Therapeutics does not currently pay a dividend.
4D Molecular Therapeutics does not currently pay a dividend.
To buy shares in 4D Molecular Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $29.60, shares in 4D Molecular Therapeutics had a market capitalisation of $791.67m.
Here are the trading details for 4D Molecular Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: FDMT
Based on an overall assessment of its quality, value and momentum 4D Molecular Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in 4D Molecular Therapeutics is $52.33. That is 76.79% above the last closing price of $29.60.
Analysts covering 4D Molecular Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.84 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 4D Molecular Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -39.75%.
As of the last closing price of $29.60, shares in 4D Molecular Therapeutics were trading -16.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for 4D Molecular Therapeutics.
4D Molecular Therapeutics' management team is headed by:
- John Milligan -
- David Kirn - CEO
- August Moretti -
- David Schaffer -
- Robert Fishman -
- Carolyne Zimmermann -
- Tony Yao -
- Jacob Chacko -
- Susannah Gray -
- Nancy Miller-Rich -
- Charles Theuer -
- Shawn Tomasello -
We do not have data on 4D Molecular Therapeutics' shareholders